Inclusion Criteria:

• Qualifying regimen defined as peginterferon alfa-2a plus ribavirin or peginterferon alfa-2b plus ribavirin for a minimum of 12 weeks.
• During qualifying regimen, subjects must have either a documented undetectable HCV-RNA within 30 days of end of treatment (EOT) and a subsequent detectable HCV-RNA during follow-up or a documented decline in HCV-RNA by >=2 log10 by Treatment Week 12
• Previously documented CHC genotype 1 infection.
• Liver biopsy with histology consistent with CHC and no other etiology.
• Subjects with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the Screening Visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC).
• Subjects participating in SPRI maintenance protocols P02570 or P02569 must have completed the study to be eligible for this protocol.
• Subject must be >=18 years of age.
• Subject must weigh between 40 kg and 125 kg.
• Subject and subject's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations.
• Subjects must be willing to give written informed consent.

Exclusion Criteria:

• Coinfection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive).
• Discontinuation of previous interferon or ribavirin regimen for an AE considered by the investigator to be possibly or probably related to ribavirin and/or interferon.
• Treatment with ribavirin within 90 days and any interferon-alpha within 1 month of Screening.
• Treatment for hepatitis C with any investigational medication. Prior treatment with herbal remedies with known hepatotoxicity.
• Treatment with any investigational drug within 30 days of the randomization visit.
• Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial.
• Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy.
• Diabetic and/or hypertensive subjects with clinically significant ocular examination findings.
• Pre-existing psychiatric conditions.
• Clinical diagnosis of substance abuse of the specified drugs within the specified timeframes
• Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study.
• Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of the skin). Subjects under evaluation for malignancy are not eligible.
• Subjects who are pregnant or nursing. Subjects who intend to become pregnant during the study period. Male subjects with partners who are, or intend to become, pregnant during the study period.
• Any other condition which, in the opinion of a physician, would make the subject unsuitable for enrollment or could interfere with the subject participating in and completing the study.
• Subjects who are part of the site personnel directly involved with this study.
• Subjects who are family members of the investigational study staff.
• Subjects who had life-threatening serious adverse event (SAE) during screening period.
• Protocol-specified hematologic, biochemical, and serologic criteria: Hemoglobin <12 g/dL for females and <13 g/dL for males; Neutrophils <1500/mm^3 (Blacks: <1200/mm^3); Platelets <100,000/mm^3; Direct bilirubin >1.5 x upper limit of normal (ULN).
• Serum albumin <lower limit of normal (LLN)
• Thyroid-stimulating hormone (TSH) >1.2 x ULN or <0.8 x LLN of laboratory reference range, with certain exceptions.
• Serum creatinine >ULN of the laboratory reference.
• Protocol-specified serum glucose concentrations.
• Protocol-specified alpha fetoprotein range.
• Prothrombin Time/Partial Thromboplastin Time (PT/PTT) values >10% above laboratory reference range.
• Anti-nuclear antibodies (ANA) >1:320.